The role of allergen-specific immunotherapy in the treatment of canine atopic dermatitis: Part 2
|
|
- Blanche Maxwell
- 5 years ago
- Views:
Transcription
1 The role of allergen-specific immunotherapy in the treatment of canine atopic dermatitis: Part 2 Sarah Warren BVetMed MSc(ClinOnc) CertVD MRCVS Regional Veterinary Dermatologist CVS UK, Southern Region MILDMAY VETERINARY CENTRE, EASTON LANE, WINCHESTER, HAMPSHIRE. SO23 7RU ABSTRACT: Allergen-specific immunotherapy is considered an effective therapy for the management of canine atopic dermatitis when relevant allergens have been identified through either intradermal or serological testing. It is an extremely safe form of treatment and serious adverse effects are uncommon. Additional antiinflammatory or symptomatic therapy during the induction phase of immunotherapy is often needed, depending on the severity of clinical signs in the individual. The long-term success of immunotherapy can be measured by the ability to taper or even withdraw these supportive therapies. DOI: /j x INTRODUCTION The indications for canine immunotherapy were discussed in Part 1 of this review, along with the types of therapy available and protocols for their administration. In Part 2, response to treatment, concurrent therapies, possible side-effects and some common questions will be considered. TREATMENT RESPONSE TO ALLERGEN-SPECIFIC IMMUNOTHERAPY Allergen-specific immunotherapy is considered an effective therapy for the management of canine atopic dermatitis when relevant allergens have been identified through either intradermal or serological testing. Fig. 2. In many cases, improvement is not seen until six-tonine months after therapy has begun, and it is recommended that at least twelve months of treatment are undertaken before discarding immunotherapy as a potential long-term management option (Figs. 1-4). If immunotherapy is shown to be successful, it should, in principle, be continued for the life of the animal in order that the signs of disease are controlled, and in order for any acquired benefits to be maintained. Figs. 1 and 2: Response to immunotherapy: atopic Weimeraner before immunotherapy and, Fig. 2, nine months after starting allergen-specific immunotherapy. Note generalised erythema and self-induced alopecia, especially over periorbital regions, muzzle, ventral neck, ventral chest and feet, before treatment, and marked improvement in coat condition nine months after starting therapy. ADDITIONAL SYMPTOMATIC THERAPY AND IMMUNOTHERAPY Additional anti-inflammatory or symptomatic therapy during the induction phase of immunotherapy is often needed and will depend on the severity of clinical signs in the individual. This may range from the use of essential fatty acid supplementation, colloidal oatmeal shampoo and antihistamines in mild cases, to topical corticosteroids such as hydrocortisone aceponate (Cortavance; Virbac) in moderate cases and glucocorticoids or ciclosporin (Atopica; Novartis) in more severe cases. Companion Animal Vol 18 January
2 Figs. 3 and 4: Same patient as in Figs. 1 and 2. Note erythema and alopecia over dorsal aspects of the feet before treatment, and, in Fig. 4, marked improvement after nine months of therapy. ADVERSE EFFECTS Allergen-specific immunotherapy is an extremely safe form of treatment and serious adverse effects are uncommon. Practitioners should, however, be aware of the potential adverse effects so that these can be recognised and treated appropriately. An increase in pruritus in the days following injection is the most common adverse effect and usually lasts for two-to-three days. Pre-treatment with antihistamine for two-to-three days until the day after administration usually overcomes the problem. Hydrocortisone aceponate spray (Cortavance; Virbac) may also be useful if pruritus is localised. If pruritus is seen consistently following injection, the dose of immunotherapy should be reduced. Injection-site reactions such as localised swelling may occur in some individuals but usually requires no treatment. More serious reactions may include: urticaria, angioedema, gastrointestinal disturbances, behavioural changes, weakness, lethargy or collapse. Anaphylaxis is of greatest concern although the risk is low (around 1%). Dogs should be kept in the practice for 30 minutes following administration of the first few doses of immunotherapy to permit prompt treatment should anaphylaxis occur. Fig. 4. If glucocorticoids or other immunosuppressive therapies are used, it is recommended that the dose be tapered, if possible, two weeks prior to starting induction of immunotherapy. As well as potentially affecting the mechanism of immunotherapy, these drugs may also interfere with detecting clinical responses to immunotherapy so that indications for altering the regime may be masked. If a steroid-free starting point is not possible, however, the lowest effective, alternate-day dose of prednisolone can be used. Anti-microbial drugs, antihistamines and essential fatty acids are considered to have no effect on responses to immunotherapy. The long-term success of immunotherapy can be measured by the ability to taper or even withdraw these supportive therapies. In some cases, however, it is not possible to withdraw other therapies completely, but immunotherapy may at least have a dose-sparing effect. Treatment of anaphylaxis l intravenous adrenaline ml diluted 1:1000 (according to effect - inject slowly) l ensure airway open and supply oxygen through an endotracheal tube if dyspnoea is present l intravenous injection of rapidly-acting glucocorticoid such as hydrocortisone sodium succinate 2-4 mg/kg l intravenous or intramuscular injection of anti-histamine such as diphenhydramine hydrochloride 1-2 mg/kg l hospitalisation, intravenous fluid therapy, supportive intensive therapy if required. FREQUENTLY ASKED QUESTIONS Can immunotherapy be given during pregnancy and lactation? Dogs diagnosed with atopic dermatitis should not be used for breeding, so these situations should not arise. No safety studies have been performed, however, so immunotherapy cannot be recommended during pregnancy and lactation. Can immunotherapy be given to animals with concurrent diseases? Immunotherapy is contraindicated in diseases that affect the immune system, including immunodeficiency, malignant disease and autoimmune disease. It is also contraindicated in patients with renal disease. Can immunotherapy and routine vaccination be given together? 28 Companion Animal Vol 18 January 2013
3 These should not be given at the same time. A minimum one-to-two week period between injections is recommended. Can immunotherapy be administered if an animal is unwell? The injection should be postponed if the animal is unwell or pyrexic. What happens if the immunotherapy vial has been left out of the fridge or delayed in the post? It is possible that the allergen extracts could be ineffective in these situations and the vial should be replaced. Vials should be stored at 2-8 C in a refrigerator in the original packaging. What if the vial has been frozen inadvertently? Freezing will denature the allergens so the vial should be replaced What to do if an immunotherapy vial has gone out of date? The vial should not be used past the expiry date. If the immunotherapy has become discoloured, can it still be used? Discolouration is possible over time and some allergen extracts are naturally darker than others. This is not associated with loss of potency. If brown precipitates develop, however, the vial should be discarded. A patient has missed an injection, when should the next one be given? During induction, if only one dose has been missed over a short time period, it may be possible to restart with the missed dose and continue with the protocol. If a longer time period has elapsed, it may be advisable to return to a lower dose initially. The protocols provided are a guide only - it is not vital to follow this to the day, e.g. if a dose falls on a weekend when the owners are away, choosing the nearest day will suffice. The owner has discontinued therapy for some time and now symptoms have recurred - can we restart therapy where we left off? The longer the time since the last injection was given, the lower the dose should be on restarting therapy. In some cases it may be safer to restart the induction protocol. FURTHER READING BOUSQUET, J., LOCKEY, R., MALLING, H. J., et al. (1998) Allergen immunotherapy; therapeutic vaccines for allergic diseases. World Health Organisation. American Academy of Allergy, Asthma and Immunology. Annals of Allergy, Asthma and Immunology 81: DEBOER, D. J. and HILLIER, A. (2001) The ACVD task force on canine atopic dermatitis (XVI): laboratory evaluation of dogs with atopic dermatitis with serum-based allergy tests. Veterinary Immunology and Immunopathology 81: GOLDMAN, C., ROSSER, E., PETERSON, A. and HAUPTMAN, J. (2010) Investigation on the effects of ciclosporin (Atopica) on intradermal test reactivity and allergen-specific immunoglobulin IgE serology in atopic dogs. Veterinary Dermatology 21:
4 GRIFFIN, C. E. and HILLIER, A. (2001) The ACVD task force on canine atopic dermatitis (XXIV): allergen specific immunotherapy. Veterinary Immunology and Immunopathology. 81: HILLIER, A. and DEBOER, D. J. (2001) The ACVD task force on canine atopic dermatitis (XVII): Intradermal testing. Veterinary Immunology and Immunopathology 81: LEE, K. W., BLANKENSHIP, Z. M., MCCURRY, M., ESCH, R. E., DEBOER, D. J. and MARSELLA, R. (2009) Performance characteristics of a monoclonal antibody cocktail-based ELISA for detection of allergen-specific IgE in dogs and comparison with a high affinity IgE receptor-based ELISA. Veterinary Dermatology 20: LOWENSTEIN, C. and MULLER, R. S. (2008) A review of allergenspecific immunotherapy in human and veterinary medicine. Veterinary Dermatology 20: MUELLER, R. S., FIESELER, K. V., ROSYCHUK, R. A. and GREENWALT, T. (2005) Intradermal testing with the storage mite Tyrophagus putrescentiae in normal dogs and dogs with atopic dermatitis in Colorado. Veterinary Dermatology 16: NUTTALL, T. J., THODAY, K. L., VAN DEN BROEK, A. et al. (1998) Retrospective survey of allergen specific immunotherapy in canine atopy. Veterinary Record 143: OLIVRY, T. (2010) New diagnostic criteria for canine atopic dermatitis (Letter to the editor) Veterinary Dermatology 21: OLIVRY, T., DEBOER, D. J., FAVROT., C., JACKSON, H. A., MUELLER, R. S., NUTTAL, T. and PRELAUD, P. (2010) ACDV task force on canine atopic dermatitis: Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology 21: ROQUE., J. B., O LEARY, C., KYAW-TANNER, M., et al. (2011) High allergen-specific serum immunoglobulin E levels in non-atopic West Highland white terriers. Veterinary Dermatology 22: ROSENBAUM, M. R., ESCH, R. E. and SCHWARTZMAN, R. M. (1996) Effects of mould proteases on the biological activity of allergenic pollen extracts. American Journal of Veterinary Research 57: SCHNABL, B., BETTENAY, S. V., DOW, K. and MUELLER, R. S. (2006) Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Veterinary Record 158: ADDENDUM In Part 1 of this series (UKVet Vol 17.9) sub-lingual immunotherapy (SLIT) was discussed as a new alternative route of administration of allergens for immunotherapy, and until now has only been commercially available in the USA. In November of this year, Axiom Veterinary Laboratories Ltd started distributing ACTT Allergy TM Drops (Bio-Medical Services). This product does not possess a UK licence as yet, but is available upon application for a Special Treatment Certificate (STC). ACTT Allergy TM Drops are prepared in a palatable glycerine solution and are administered twice daily to the sub-lingual mucosa via a simple pump dispenser applied under the dog s tongue or inside the lip or cheek. Food and water can interfere with the absorption of the therapy therefore the drops should be given at least 10 minutes before either. Each initial treatment set begins with a three-bottle series with increasing concentration of allergen in each. The initial induction protocol is rapid and allows the dog to reach therapeutic dosage in four weeks. Maintenance is then continued using a twice daily regime and tailored to the individuals response. The effective approach to allergy in dogs and cats starts with the Artuvetrin Serum Test. The outcome of this test, combined with our technical support and advice, will help you to fi ght the cause of allergies. ALK-Abelló Ltd - 1 Manor Park, Manor Farm Road, Reading RG2 0NA, United Kingdom. Tel: +44-(0) Fax: +44-(0) artuvetrin@alk.net
5 Although further studies are needed to fully evaluate this route of immunotherapy, the pilot studies have shown encouraging results with approximately 70% of dogs showing improvement in their symptoms. Furthermore, SLIT is extremely safe with systemic adverse events virtually unreported in the literature; it may also be effective in patients who have previously failed subcutaneously immunotherapy and safe in patients who have experienced serious systemic effects with previously administered subcutaneous immunotherapy. Mild reactions can include facial pruritus, pruritus, GI upset or lethargy. Sub-lingual immunotherapy provides an alternative route of administration of allergens for immunotherapy and may be useful for those owners or dogs who are needle adverse, who have a history of intolerance to subcutaneous immunotherapy and may even increase compliance in those owners happy to administer an oral medication twice daily. REFERENCE ADDITIONS D. J. DeBOER, M. VERBRUGGE and M. MORRIS Pilot trial of sublingual immunotherapy (SLIT) in mite-sensitive atopic dogs. Veterinary Dermatology 21:325. D. J. DeBOER, M. MORRIS Multicentre Open Trial Demonstrates Efficacy of Sublingual Immunotherapy in Canine Atopic Dermatitis. Veterinary Dermatology 23 (Supplement 1), 65. NEWSREVIEW THE POSITIVE EXTERNALITIES OF PET OWNERSHIP OR PETS ARE GOOD FOR GOVERNMENT The benefits of pet ownership also extend to the Chancellor as the Autumn statement approaches. The Pet Advisory Committee (PAC) using the government s own figures estimates that pet lovers spent almost 6 billion in 2010 and contributed more than 2 billion a year to the nation s coffers in taxes. Additionally there are other less visible benefits that help balance the Chancellor s books. Independent studies indicate that the health benefits of pet ownership (and around of half of UK households do) effectively save the NHS as much as 1.5 billion a year. As the Euro crisis deepens, other Finance Ministers in the EU should also take note. Throughout the EU in 2010, owners spent 29 billion on their pets (equating to 12 billion in tax revenues) and social scientists studying the health benefits of pet ownership in Germany estimated savings of 5.5 billion annually. The Pet Advisory Committee points out that not everything can be reduced to hard cash as chair Tracey Crouch MP says What this research shows is the positive contribution pets and their owners make to the economy and towards a healthy society. While the contribution to the economy is easier to identify, the companionship, interaction and exercise pets can give to their owners, in particular the elderly, and the effect this has on their well-being is of equal worth to individuals and society as a whole. CONTINUING PROFESSIONAL DEVELOPMENT In order to test your understanding of this article, answer these multiple choice questions, or if you are a subscriber, go online at and find many more multiple choice questions to test your understanding. 1. Which one(s) of these statements is true: a. Allergen-specific immunotherapy should be used as a sole treatment for canine atopic dermatitis. b. It is not possible to use other therapies alongside allergen-specific immunotherapy. c. The dosage and frequency of injections should be maintained at the same volume every four weeks whatever the circumstances. d. Allergen-specific immunotherapy is 100% effective. e. There may be a slight increase in pruritus two-tothree days following the injections. 2. True or false: It is possible for individuals to acquire further allergies following initial allergy testing, especially if tested in the early stages of their disease. a. True b. False 3. In many cases, how long may it take before the benefits of immunotherapy are seen: a. Two years b. Six-to-nine months c. One-to-two months d. Five years e. One-to-two weeks Answers to the above questions appear on page 47 of the print version, and as supporting information in the online version of this article at: Are you a subscriber? Then more MCQS are available online at If answering these and the additional MCQs through then answers will be provided as part of the marking and submission process to achieve a Certificate of Completion, which you can print off and keep as part of your Professional Development Portfolio. If you would like to submit an article for publication contact the editorial panel at ukvet@ukvet.co.uk Companion Animal Vol 18 January
Quick Guide: SLIT Protocol
Quick Guide: SLIT Protocol Mixing allergy drops in your dermatology practice. Countless Pet Allergies. One Solution. ACTTallergy.com V009v2 You have a choice for your allergy products with the ACTT Allergy
More informationCutaneous adverse food reactions in the canine patient
Cutaneous adverse food reactions in the canine patient D R. M I C H A E L A. R O S S I, D V M, M N S D I P. A M E R I C A N C O L L E G E O F V E T E R I N A R Y D E R M A T O L O G Y C O A S T A L V E
More informationAllergen-Specific Immunotherapy: Hocus Pocus or Legitimate Therapy Holly Roberts, DVM, MS, DACVD
Allergen-Specific Immunotherapy: Hocus Pocus or Legitimate Therapy Holly Roberts, DVM, MS, DACVD 1. Allergic Disease a. Atopic Dermatitis i. Seasonal ii. Nonseasonal iii. Seasonally nonseasonal b. Cutaneous
More informationThe Itch that can t be scratched: Feline Allergic Disease Holly Roberts, DVM, MS, DACVD Blue Pearl Veterinary Specialists San Antonio, TX
The Itch that can t be scratched: Feline Allergic Disease Holly Roberts, DVM, MS, DACVD Blue Pearl Veterinary Specialists San Antonio, TX 1. Diagnosing Feline Allergies a. Symptomatic patient i. Pruritus
More informationMVMA 2014 Cutting Edge Sandra N. Koch, DVM, MS, DACVD. Treatment of Canine Atopic Dermatitis: Practical Guidelines and Updates
MVMA 2014 Cutting Edge Sandra N. Koch, DVM, MS, DACVD Treatment of Canine Atopic Dermatitis: Practical Guidelines and Updates Summary Canine atopic dermatitis remains one of the most difficult conditions
More informationAtopic dermatitis and the skin barrier
Atopic dermatitis and the skin barrier Dani Hoolahan BVSc BVMS DACVD Veterinary Dermatology Clinic: Sydney, Canberra, Newcastle, Tasmania, Kiama, Coffs Harbour Newcastle Animal Referral and Emergency Centre
More informationHow (& when, & why) I diagnose atopy - and then what do I do??
How (& when, & why) I diagnose atopy - and then what do I do?? Stephen D. White, DVM, Diplomate ACVD Professor, School of Veterinary Medicine University of California What exactly IS atopy (aka atopic
More informationINVESTIGATIONS & PROCEDURES IN PULMONOLOGY. Immunotherapy in Asthma Dr. Zia Hashim
INVESTIGATIONS & PROCEDURES IN PULMONOLOGY Immunotherapy in Asthma Dr. Zia Hashim Definition Involves Administration of gradually increasing quantities of specific allergens to patients with IgE-mediated
More informationCANINE ATOPY : A THERAPEUTIC UPDATE
1 CANINE ATOPY : A THERAPEUTIC UPDATE Rod A.W. Rosychuk DVM, DACVIM Contemporary therapies for canine atopy address our ever expanding knowledge regarding the pathogenesis of this disease : transcutaneous
More informationComparison of IgE test results with intradermal skin tests for dust mites and storage mites in atopic dogs
Polish Journal of Veterinary Sciences Vol. 18, No. 2 (2015), 351 356 DOI 10.1515/pjvs-2015-0045 Original article Comparison of IgE test results with intradermal skin tests for dust mites and storage mites
More informationAllergy Skin Prick Testing
Allergy Skin Prick Testing What is allergy? The term allergy is often applied erroneously to a variety of symptoms induced by exposure to a wide range of environmental or ingested agents. True allergy
More informationCanine Atopic Dermatitis & Immunotherapy
STEP 1: Comprehensive Overview Canine Atopic Dermatitis & Immunotherapy Jennifer Schissler Pendergraft, DVM, MS, DACVD Colorado State University Canine atopic dermatitis (CAD), one of the most common diagnoses
More informationDiagnosis of canine atopic dermatitis (including food allergy)
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Diagnosis of canine atopic dermatitis (including food allergy) Favrot,
More informationAtopy. What are the signs of atopy?
Atopy Atopy is a fairly common condition in dogs. Animals with atopy are allergic to substances in the environment that are inhaled or absorbed through the skin. The resulting allergic reaction is seen
More informationSkin prick testing: Guidelines for GPs
INDEX Summary Offered testing but where Allergens precautions are taken Skin prick testing Other concerns Caution Skin testing is not useful in these following conditions When skin testing is uninterpretable
More informationCANINE DIETARY AND ENVIRONMENTAL HYPERSENSITIVITY
CANINE DIETARY AND ENVIRONMENTAL HYPERSENSITIVITY Canine allergens What are the most common canine allergens? Common canine allergens What are the most common canine allergens? Flea allergy dermatitis
More informationTHE COMPLETE ALLERGY SERVICE. Immunotherapy TARGETING THE ROOT CAUSE OF ALLERGY INNOVATION IN ANIMAL HEALTHCARE
THE COMPLETE ALLERGY SERVICE Immunotherapy TARGETING THE ROOT CAUSE OF ALLERGY INNOVATION IN ANIMAL HEALTHCARE WHAT IS IMMUNOTHERAPY? Allergen-specific immunotherapy (hyposensitisation or desensitisation
More informationGLORIA Module 4: Allergen Specific Immunotherapy Its safe use: A New Zealand perspective
Update on desensitisation Associate Professor Rohan Ameratunga GLORIA Module 4: Allergen Specific Immunotherapy Its safe use: A New Zealand perspective Procedure Allergen immunotherapy is the administration
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationFeline dermatology: signs, diagnosis, skin disorder types and treatment
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline dermatology: signs, diagnosis, skin disorder types and treatment Author : Rachel Sant Categories : RVNs Date : June
More informationAllergy Immunotherapy in the Primary Care Setting
Allergy Immunotherapy in the Primary Care Setting New York State College Health Association 2008 COMBINED ANNUAL MEETING October 2008 Mary Madsen RN BC University of Rochester Issues in Primary Care Practice
More informationPackage leaflet: Information for the user. Pharmalgen Bee Venom Pharmalgen Wasp Venom. 100μg/ml. powder and solvent for solution for injection
Package leaflet: Information for the user Pharmalgen Bee Venom Pharmalgen Wasp Venom 100μg/ml powder and solvent for solution for injection Read all of this leaflet carefully before you start using this
More informationUpdates on Feline Atopic Dermatitis (or should we say CATopy?)
Updates on Feline Atopic Dermatitis (or should we say CATopy?) Sandra N. Koch, DVM, MS, DACVD Associate Professor, Dermatology College of Veterinary Medicine, University of Minnesota INTRODUCTION Despite
More informationAs you begin this build-up phase there are several factors to keep in mind concerning your treatment:
SLIT IMMUNOTHERAPY INSTRUCTIONS David R. Scott, M.D./William A. Scott, M.D. Congratulations on beginning your new sublingual immunotherapy (SLIT) prescription! The initial 30 doses are advancement doses.
More informationUsing essential fatty acids in canine atopic dermatitis
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Using essential fatty acids in canine atopic dermatitis Author : Eva Espadale Reballi Categories : Companion animal, Vets
More informationTreatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)
Olivry et al. BMC Veterinary Research (2015) 11:210 DOI 10.1186/s12917-015-0514-6 CORRESPONDENCE Open Access Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee
More informationManagement of an immediate adverse event following immunisation
Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.
More informationBOLSTRAN Injection (Omalizumab)
Published on: 27 Feb 2017 BOLSTRAN Injection (Omalizumab) Composition Active Substance Omalizumab is a humanized monoclonal antibody manufactured from a mammalian cell line. One vial of BOLSTRAN 150 mg
More informationAntiallergics and drugs used in anaphylaxis
Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis The H 1 -receptor antagonists are generally referred to as antihistamines. They inhibit the wheal, pruritus, sneezing
More informationTREATING MALASSEZIA DERMATITIS
Vet Times The website for the veterinary profession https://www.vettimes.co.uk TREATING MALASSEZIA DERMATITIS Author : Katerina Varjonen, Ross Bond Categories : Vets Date : May 25, 2009 Katerina Varjonen
More informationIMMUNOTHERAPY IN ALLERGIC RHINITIS
Rhinology research Chair Weekly Activity, King Saud University IMMUNOTHERAPY IN ALLERGIC RHINITIS E V I D E N C E D - B A S E O V E R V I E W O F T H E R U L E O F I M M U N O T H E R A P Y I N A L L E
More informationSolving the Allergy Puzzle. Amy Haarstad DVM DACVD
Solving the Allergy Puzzle Amy Haarstad DVM DACVD Diagnosis of Exclusion History Physical Exam Diagnostics Other Causes of Itch Ectoparasites Fleas Sarcoptes Bacterial Staphylococcus Pseudintermedius Fungal
More informationPRIMARY CARE PRACTICE GUIDELINES
Community Mgmt Team - 1 of 6 1. OUTCOME To identify anaphylaxis in the primary care setting and provide an evidence informed emergency response utilizing the most current provincial and federal practice
More informationDrew University Health Service 36 Madison Avenue Madison, New Jersey Tel: Fax:
Dear Student, Enclosed you will find our policies, procedures and student consent form for your allergy immunotherapy. We ask that you read them carefully, sign the consent form, and take the physician
More informationStudent Health Center
Referring Allergist Agreement Your patient is requesting that the University of Mary Washington Student Health Center (UMWSHC) administer allergy extracts provided by your office. Consistent with our policies
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 6 Last Review Date: March 18, 2016 Xolair Description Xolair (omalizumab)
More informationREFERRAL GUIDELINES - SUMMARY
Clinical Immunology & Allergy Unit LEEDS TEACHING HOSPITALS NHS TRUST REFERRAL GUIDELINES - SUMMARY THESE GUIDELINES ARE DESIGNED TO ENSURE THAT PATIENTS REQUIRING SECONDARY CARE ARE SEEN EFFICIENTLY AND
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 7 Last Review Date: September 15, 2016 Xolair Description Xolair (omalizumab)
More informationPART III: CONSUMER INFORMATION XOLAIR (omalizumab)
PART III: CONSUMER INFORMATION XOLAIR (omalizumab) This leaflet is part III of a three-part "Product Monograph" published when XOLAIR was approved for sale in Canada and is designed specifically for Consumers.
More informationInformation and Consent for Administration of Immunotherapy (Allergy Injections)
Information and Consent for Administration of Immunotherapy (Allergy Injections) PLEASE READ AND BE CERTAIN THAT YOU UNDERSTAND THE FOLLOWING INFORMATION PRIOR TO SIGNING THIS CONSENT FOR TREATMENT PURPOSE
More informationWILLIAM B. COBB, M.D. KEITH MATHENY, M.D. EWEN TSENG, M.D. KENNY CARTER, M.D.
WILLIAM B. COBB, M.D. KEITH MATHENY, M.D. EWEN TSENG, M.D. KENNY CARTER, M.D. INSTRUCTIONS FOR ALLERGY SKIN TESTING FOR SUBLINGUAL DROPS TREATMENT SKIN TESTING 1. Discontinue all antihistamines, oral or
More informationEffectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis
Plant and Neradilek BMC Veterinary Research (2017) 13:4 DOI 10.1186/s12917-016-0917-z RESEARCH ARTICLE Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis
More informationScottish Medicines Consortium
Scottish Medicines Consortium Standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate (Grazax ) No. (367/07) ALK-Abellό Ltd 6 April 2007 The Scottish
More informationProduct Information BROWN SNAKE ANTIVENOM AUST R 74897
Product Information APPROVED NAME BROWN SNAKE ANTIVENOM AUST R 74897 DESCRIPTION BROWN SNAKE ANTIVENOM is prepared from the plasma of horses immunised with the venom of the brown snake (Pseudonaja textilis).
More informationPractical Course Allergen Immunotherapy (AIT) How to be effective. Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil
Practical Course Allergen Immunotherapy (AIT) How to be effective Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil Allergen immunotherapy - beginning Dunbar almost died with first inoculation 1911 Noon
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationCanine Atopic Dermatitis (Atopy)
Canine Atopic Dermatitis (Atopy) What is atopic dermatitis? Atopic dermatitis (atopy) is an inherited predisposition to develop allergic symptoms after repeated exposure to some otherwise harmless substance.
More informationScope of Practice Allergy Skin Testing in Australia In relation to revised Medicare Benefits Schedule item numbers effective 1 November 2018
Scope of Practice Allergy Skin Testing in Australia In relation to revised Medicare Benefits Schedule item numbers effective 1 November 2018 A. Introduction The Australasian Society of Clinical Immunology
More informationdmega3 The Evidence Based Veterinary Medicine (EBVM) approach to Atopic Dermatitis and related consequences PHA Highly purified Omega 3 from fish oil
PHA INNOVATION dmega3 The Evidence Based Veterinary Medicine () approach to Atopic Dermatitis and related consequences DOI :10.111 11/ 1 j.1 365-3164. 2010.00889.x Thisarticle isendorsed by theworldsm
More informationAssociate Professor Rohan Ameratunga Immunologist & Allergist, Auckland
Associate Professor Rohan Ameratunga Immunologist & Allergist, Auckland Update on desensitisation Associate Professor Rohan Ameratunga GLORIA Module 4: Allergen Specific Immunotherapy A New Zealand perspective
More informationDAP Clavulanic Powder and solvent for injectable suspension.
DAP Clavulanic Powder and solvent for injectable suspension. Read all of this leaflet carefully before you start using this medicine because it contains important information fon you. - Keep this leaflet.
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationPolicy for the use of intravenous Iron Dextran (CosmoFer )
Policy for the use of intravenous Iron Dextran (CosmoFer ) Sharepoint Location Clinical Policies and Guidelines Sharepoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More informationATOPIC DERMATITIS IN THE DOG
ATOPIC DERMATITIS IN THE DOG by Stephen Shaw, BVetMed, CertSAD, MRCVS In 1976, a survey of skin disease in guide dogs failed to mention atopic skin disease. Since then, there has been an increased awareness
More informationDOG AND CAT ALLERGIES Vicky L. Ograin, MBA, RVT, VTS (Nutrition) Academy of Veterinary Nutrition Technicians
DOG AND CAT ALLERGIES Vicky L. Ograin, MBA, RVT, VTS (Nutrition) Academy of Veterinary Nutrition Technicians Introduction Allergic skin disease is one of the most common types of skin disorders. Allergies
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationManagement of Canine Atopic Dermatitis
Management of Canine Atopic Dermatitis Avoidance/Elimination of Allergens Remove feathers, kapok, wool House dust mite control measures Remove carpets, blinds, plants, upholstered furniture, clutter Use
More informationSUMMARY OF PRODUCT CHARACTERISTICS. POLLINEX Trees, 300, 800 and 2000 Standardised Units (SU)/0.5ml, suspension for injection
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT POLLINEX Trees, 300, 800 and 2000 Standardised Units (SU)/0.5ml, suspension for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION POLLINEX
More informationSUMMARY OF PRODUCT CHARACTERISTICS. POLLINEX Trees Extension Course, 2000 Standardised Units (SU)/0.5ml, suspension for injection
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT POLLINEX Trees Extension Course, 2000 Standardised Units (SU)/0.5ml, suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationMeningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135
MENOMUNE ACYW-135 Meningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135 Description The vaccine is a freeze-dried preparation of the group specific antigens from Neisseria meningitidis,
More informationUse of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015
Use of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015 Disclosures Speakers bureau/consultant: AZ, Genentech/Novartis,
More informationAssessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy
Assessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy Tolly Epstein, MD, MS Assistant Professor of Clinical Medicine Division of Immunology, Allergy & Rheumatology University
More informationMANAGING COMMON PRESENTATIONS OF ALLERGY IN PRIMARY CARE. Helen Bourne Consultant Immunologist
MANAGING COMMON PRESENTATIONS OF ALLERGY IN PRIMARY CARE Helen Bourne Consultant Immunologist AIMS Presentation of Allergic Disease in Adults Rhinitis/ Rhinoconjuctivitis Urticaria and Angioedema Food
More informationttp://www.bsava.com/ Prevalence of adverse food reactions in 130 dogs in Italy with dermatological signs: a retrospective study PAPER
ttp://www.bsava.com/ PAPER Prevalence of adverse food reactions in 130 dogs in Italy with dermatological signs: a retrospective study OBJECTIVES: To determine the prevalence of adverse food reactions (AFRs)
More informationCONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM
CONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM Dear Allergist: Your patient,, would like to continue allergy injections in our health center while
More informationMEDICAL EMERGENCIES (PART 1) IDENTIFYING AT RISK PATIENTS AND IDENTIFYING THE CONTENTS OF THE EMERGENCY DRUG KIT
MEDICAL EMERGENCIES (PART 1) IDENTIFYING AT RISK PATIENTS AND IDENTIFYING THE CONTENTS OF THE EMERGENCY DRUG KIT Aims To explain the categories of patients that may be considered as being at risk during
More informationSeasonal Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinoconjunctivitis Allergic rhinoconjunctivitis is a common condition. Most patients can achieve good symptom control through allergen avoidance and pharmacotherapy with non-sedating
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Emerade 150 micrograms solution for injection in pre-filled pen Emerade 300 micrograms solution for injection in pre-filled pen Emerade 500 micrograms solution
More informatione. Elm Correct Question 2 Which preservative/adjuvant has the greatest potential to breakdown immunotherapy because of protease activity? a.
Allergen Immunotherapy Practical Quiz Question 1 Which of the following pollens shows cross-reactivity with birch pollen? a. Alder b. Olive c. Ash d. Black walnut e. Elm Question 2 Which preservative/adjuvant
More informationFood Allergies. (Demkin). That is approximately two million kids. That number only represents children, but
McCurry!1 Bailey McCurry Kennon Biology I Honors 1 May 2018 Food Allergies Food allergies are becoming more common in today s society. More people have allergies than you might think. Research says that
More informationPOLYVALENT SNAKE ANTIVENOM Product Information 1(5) Product Information POLYVALENT SNAKE ANTIVENOM (AUSTRALIA - PAPUA NEW GUINEA) AUST R 74899
POLYVALENT SNAKE ANTIVENOM Product Information 1(5) Product Information NAME OF THE MEDICINE POLYVALENT SNAKE ANTIVENOM (AUSTRALIA - PAPUA NEW GUINEA) AUST R 74899 DESCRIPTION POLYVALENT SNAKE ANTIVENOM
More informationPRODUCT INFORMATION INFLUVAC. NAME OF THE MEDICINE Influvac inactivated influenza vaccine (surface antigen)
PRODUCT INFORMATION INFLUVAC NAME OF THE MEDICINE Influvac inactivated influenza vaccine (surface antigen) DESCRIPTION Influvac is a clear colourless suspension for injection. It is an egg-grown, inactivated
More informationD-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin
Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using
More informationCenters. Austria (2), Germany (5), Belgium (1), Netherlands (1), Denmark (1), Slovenia (1)
Study CS-BM32-003 Sponsor Biomay Protocol title Phase IIb study on the safety and efficacy of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy Clinical trial phase Phase
More informationHAVRIX 1440 and HAVRIX Junior
HAVRIX 1440 and HAVRIX Junior Inactivated Hepatitis A Virus Vaccine Consumer Medicine Information Leaflet In this leaflet, HAVRIX refers to the use of both HAVRIX 1440 for adults and HAVRIX Junior for
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationAmaury Briand, DV, ECVD* Pascal Prélaud, DV, ECVD* Noelle Cochet-Faivre, DV, ECVD* Laurent Drouet**
Safety Evaluation of Allergen Specific Immunotherapy without an Induction Phase Using Calcium Phosphate Adjuvanted Allergenic Extracts in Atopic Dogs: A Retrospective Study of One Hundred Eighty Five Cases
More informationFood allergy in children. nice bulletin. NICE Bulletin Food Allergy in Chlidren.indd 1
nice bulletin Food allergy in children NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin Food Allergy in Chlidren.indd 1 23/01/2012 11:04
More informationXOLAIR (omalizumab) Prior Authorization
MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationHypersensitivity diseases
Hypersensitivity diseases Downloaded from: StudentConsult (on 18 July 2006 11:40 AM) 2005 Elsevier Type-I Hypersensitivity Basic terms Type-I = Early= IgE-mediated = Atopic = Anaphylactic type of hypersensitivity
More informationA VET NURSES GUIDE TO WORKING UP THE ALLERGIC PATIENT
A VET NURSES GUIDE TO WORKING UP THE ALLERGIC PATIENT B Y E L L I E C L AR K R V N T H E S K I N V E T 1 WHERE DO WE START?! COMMON CAUSES OF SKIN DISEASE Allergies Ectoparasites Infectious organisms Neoplasia
More informationGUIDE TO... Latex allergy. Learning outcomes. This guide is supported by an educational grant from
GUIDE Janet Pickles is Chairwoman, RA Medical Services Ltd, Steeton, West Yorkshire Email: janet@ramedical.com TO... Learning outcomes After reading this Guide to Latex Allergy you should: n Understand
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT VANGUARD CPV-L 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Quantity per 1 ml dose Active substance(s): Live attenuated canine Parvovirus, strain NL-35-D, low passage,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ingelvac CircoFLEX suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1 ml)
More informationClinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013
1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT
More informationFujimura Animal Allergy Hospital, Aomatanihigashi , Minou-shi, Osaka , Japan
Veterinary Medicine, Article ID 492735, 5 pages http://dx.doi.org/1.1155/214/492735 Research Article Influence of a Diester Glucocorticoid Spray on the Cortisol Level and the CCR4 + CD4 + Lymphocytes in
More information5/9/2017. Another Itchy Dog. Skin Diseases are Common. Rule Out Infectious Causes of Itching Prior to Diagnosing Allergy. 2011: VPI Pet Insurance 1
Another Itchy Dog New Understanding of the Pathophysiology of Canine Allergic Disease Dr. Kimberly Greene- DVM, PSV Midwest Skin Diseases are Common 2011: VPI Pet Insurance 1 1. 2. 3. Ear Infections Skin
More informationWhat are Allergy shots / SCIT?
Allergy diagnosis must be made accurately with correct history and tests including the skin prick test and the blood test like immunocap / Phadiatop study. This once made will help decide the dose and
More informationPRODUCT INFORMATION INFLUVAC. NAME OF THE MEDICINE Influvac inactivated influenza vaccine (surface antigen)
PRODUCT INFORMATION INFLUVAC NAME OF THE MEDICINE Influvac inactivated influenza vaccine (surface antigen) DESCRIPTION Influvac is a clear colourless suspension for injection. It is an egg-grown, inactivated
More informationACARIZAX PRODUCT INFORMATION AUST R NAME OF THE MEDICINE. ACARIZAX 12 SQ-HDM oral lyophilisate. DESCRIPTION. ACARIZAX is allergy immunotherapy.
ACARIZAX PRODUCT INFORMATION AUST R 250392 NAME OF THE MEDICINE ACARIZAX 12 SQ-HDM oral lyophilisate. DESCRIPTION ACARIZAX is allergy immunotherapy. ACARIZAX oral lyophilisate tablets contain 12 SQ-HDM
More informationAzelastine Nasal Spray 1 mg / 1 ml
Package Leaflet: Information for the User Allergodil 0,1% nasal spray, solution Active substance: Azelastine hydrochloride Read all of this leaflet carefully because it contains important information for
More informationTYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)
TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2
More informationCAUTION: You must refer to the intranet for the most recent version of this procedural document.
Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion
More information